- Home
- SVII vs ABEO Comparison
SVII vs ABEO Comparison
Compare SVII & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- ABEO
- Stock Information
- Founded
- SVII 2021
- ABEO N/A
- Country
- SVII United States
- ABEO United States
- Employees
- SVII N/A
- ABEO N/A
- Industry
- SVII Blank Checks
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- ABEO Health Care
- Exchange
- SVII Nasdaq
- ABEO Nasdaq
- Market Cap
- SVII 111.1M
- ABEO 247.8M
- IPO Year
- SVII 2022
- ABEO 1980
- Fundamental
- Price
- SVII $11.22
- ABEO $5.70
- Analyst Decision
- SVII
- ABEO Strong Buy
- Analyst Count
- SVII 0
- ABEO 3
- Target Price
- SVII N/A
- ABEO $18.00
- AVG Volume (30 Days)
- SVII 74.3K
- ABEO 225.2K
- Earning Date
- SVII 01-01-0001
- ABEO 11-14-2024
- Dividend Yield
- SVII N/A
- ABEO N/A
- EPS Growth
- SVII 13.16
- ABEO N/A
- EPS
- SVII 0.36
- ABEO N/A
- Revenue
- SVII N/A
- ABEO N/A
- Revenue This Year
- SVII N/A
- ABEO N/A
- Revenue Next Year
- SVII N/A
- ABEO $18,714.71
- P/E Ratio
- SVII $31.11
- ABEO N/A
- Revenue Growth
- SVII N/A
- ABEO 147.52
- 52 Week Low
- SVII $10.81
- ABEO $3.05
- 52 Week High
- SVII $11.70
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- SVII 39.53
- ABEO 34.30
- Support Level
- SVII $11.20
- ABEO $5.45
- Resistance Level
- SVII $11.24
- ABEO $6.04
- Average True Range (ATR)
- SVII 0.01
- ABEO 0.19
- MACD
- SVII 0.01
- ABEO -0.04
- Stochastic Oscillator
- SVII 40.00
- ABEO 19.47
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.